UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $410,000 Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 17.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,356 shares of the company’s stock after purchasing an additional 7,765 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Y-mAbs Therapeutics were worth $410,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new position in Y-mAbs Therapeutics in the 4th quarter valued at $46,000. ProShare Advisors LLC acquired a new position in Y-mAbs Therapeutics in the 4th quarter valued at $99,000. Wells Fargo & Company MN raised its holdings in Y-mAbs Therapeutics by 54.1% in the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after acquiring an additional 6,131 shares in the last quarter. XTX Topco Ltd raised its holdings in Y-mAbs Therapeutics by 83.8% in the 4th quarter. XTX Topco Ltd now owns 20,768 shares of the company’s stock valued at $163,000 after acquiring an additional 9,468 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock valued at $174,000 after acquiring an additional 1,903 shares in the last quarter. 70.85% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright dropped their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Monday, May 19th. Truist Financial dropped their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. Wedbush reiterated an “outperform” rating and issued a $18.00 price target (down previously from $21.00) on shares of Y-mAbs Therapeutics in a research note on Wednesday, May 28th. Finally, Oppenheimer decreased their price target on Y-mAbs Therapeutics from $20.00 to $15.00 and set an “outperform” rating on the stock in a research note on Thursday, May 29th. Two investment analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $15.60.

Y-mAbs Therapeutics Stock Down 3.5%

Shares of YMAB stock opened at $4.93 on Thursday. The firm has a market capitalization of $223.25 million, a P/E ratio of -9.13 and a beta of 0.52. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $16.11. The stock’s fifty day simple moving average is $4.42 and its 200 day simple moving average is $6.05.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. As a group, equities research analysts expect that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.